Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33809604)
Watch
English
New schedules of interferon for chronic hepatitis C.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
review article
1 reference
stated in
Europe PubMed Central
title
New schedules of interferon for chronic hepatitis C.
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
main subject
chronic hepatitis
1 reference
based on heuristic
inferred from title
author name string
Davis GL
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
publication date
1 January 1999
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
published in
Journal of Hepatology
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
volume
31 Suppl 1
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
page(s)
227-231
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
cites work
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon for non-A, non-B chronic hepatitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular mechanisms of action of ribavirin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A pilot study of ribavirin therapy for chronic hepatitis C
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Variables that influence response to different interferon schedules in chronic hepatitis C and predictive models
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Side effects of high-dose interferon therapy for chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Raising the dose of interferon does not improve the response in chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effective administration methods and dosages of interferon therapy for chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980407-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0168-8278(99)80407-3
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
PubMed ID
10622593
1 reference
stated in
Europe PubMed Central
PubMed ID
10622593
retrieved
29 July 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
